<p>Sawyer &amp; Company Inc 在第一季度减持了 Amgen Inc.（纳斯达克股票代码：AMGN - 免费报告）的持股比例，根据最近向证券交易委员会提交的文件。该公司在此期间卖出了 29,752 股，持有这家医疗研究公司的股票 15,853 股。在 Sawyer &amp; Company Inc 的投资组合中，Amgen 占比 1.8%，是其第 17 大持仓。截至最近一个季度末，Sawyer &amp; Company Inc 对 Amgen 的持股价值为 4,507,000 美元。</p>
<ul>
<li>Moderna 股价飙升，因推出尖端个性化癌症疫苗</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也对该公司的持股进行了调整。Diversified Trust Co 在第四季度将其在 Amgen 的持股比例提高了 76.8%。Diversified Trust Co 现在拥有 37,695 股 Amgen 的股票，价值 10,857,000 美元，比之前增持了 16,376 股。Provence Wealth Management Group 在第四季度将其在 Amgen 的持股比例提高了 11.9%。Provence Wealth Management Group 现在拥有 1,445 股 Amgen 的股票，价值 416,000 美元，比之前增持了 154 股。Kinsale Capital Group Inc.在第四季度将其在 Amgen 的持股比例提高了 33.0%。Kinsale Capital Group Inc.现在拥有 11,348 股 Amgen 的股票，价值 3,269,000 美元，比之前增持了 2,814 股。Global Wealth Management Investment Advisory Inc.在第四季度将其在 Amgen 的持股比例提高了 2.4%。Global Wealth Management Investment Advisory Inc.现在拥有 4,733 股 Amgen 的股票，价值 1,363,000 美元，比之前增持了 109 股。最后，Traynor Capital Management Inc.在第四季度将其在 Amgen 的持股比例提高了 9.5%。Traynor Capital Management Inc.现在拥有 18,941 股 Amgen 的股票，价值 5,455,000 美元，比之前增持了 1,650 股。机构投资者和对冲基金拥有公司股份的 76.50%。</p>
<h2>分析师评级变动</h2>
<p>一些股票分析师最近对该股发表了意见。TD Cowen 将 Amgen 的目标股价从 370.00 美元降至 360.00 美元，并在 4 月 17 日星期三的研究报告中为该公司设定了 “买入” 评级。Truist Financial 在 4 月 12 日星期五的研究报告中重申了对 Amgen 的 “买入” 评级，并设定了 320.00 美元的价格目标。StockNews.com 在 5 月 3 日星期五的研究报告中，将 Amgen 的股票评级从 “持有” 调升至 “买入”。巴克莱在 5 月 3 日星期五的研究报告中，将 Amgen 的股票评级从 “轻仓” 调升至 “等权”，并将股票的价格目标从 230.00 美元提高至 300.00 美元。最后，阿格斯在周四的研究报告中，将 Amgen 的股票价格目标从 300.00 美元提高至 340.00 美元，并给予该股票 “买入” 评级。十位投资分析师对该股进行了持有评级，十二位分析师对该股进行了买入评级。根据 MarketBeat 的数据，Amgen 的平均评级为 “中性买入”，平均目标股价为 307.35 美元。</p>
<ul>
<li>生物科技行业接近突破：第二季度表现将优于市场吗？</li>
</ul>
<p><strong>阅读我们对 AMGN 的最新分析</strong></p>
<h2>Amgen 内部交易</h2>
<ul>
<li>7 支将推动减肥药市场的股票</li>
</ul>
<p>另外，高级副总裁 Nancy A. Grygiel 于 5 月 3 日星期五进行了一笔交易，出售了公司股票 2,117 股。这些股票的平均价格为 313.09 美元，交易总额为 662,811.53 美元。交易完成后，这位高级副总裁现在持有公司股票 9,883 股，价值 3,094,268.47 美元。该交易已在向证券交易委员会提交的法律文件中披露，可以通过此超链接获得。公司内部人士持有公司股份的比例为 0.69%。</p>
<h2>Amgen 股票表现</h2>
<ul>
<li>7 支将推动减肥药市场的股票</li>
</ul>
<p>纳斯达克 AMGN 周五开盘价为 312.45 美元。该公司的流动比率为 1.42，速动比率为 0.98，负债权益比为 11.96。该公司的市值为 167.61 亿美元，市盈率为 44.64，市盈增长比率为 2.83，贝塔系数为 0.60。该公司的 50 天简单移动平均线为 301.56 美元，200 天简单移动平均线为 292.10 美元。Amgen Inc.的一年最低价为 218.44 美元，最高价为 329.72 美元。</p>
<p>Amgen（纳斯达克股票代码：AMGN - 获取免费报告）于 5 月 2 日星期四发布了其盈利结果。该医疗研究公司报告本季度每股盈利 3.96 美元，超过分析师对 3.76 美元的共识预期 0.20 美元。Amgen 的净利润率为 12.74%，净资产收益率为 156.21%。本季度，该公司的营收为 74.5 亿美元，略高于分析师对 74.5 亿美元的预期。与去年同期相比，公司的季度营收增长了 22.0%。研究分析师预计，Amgen Inc.本财年的每股盈利将达到 19.47 美元。</p>
<h2>Amgen 公司简介（免费报告）</h2>
<p>Amgen Inc（安进公司）在全球范围内发现、开发、生产和提供人类治疗药物。该公司的主要产品包括用于治疗斑块性银屑病、类风湿关节炎和银屑病性关节炎的安达治（Enbrel）；用于治疗成年患者斑块性银屑病、银屑病性关节炎和贝赫切特氏病口腔溃疡的奥特兹拉（Otezla）；用于治疗绝经后妇女骨质疏松症的普罗利亚（Prolia）；用于预防骨相关事件的 XGEVA；降低心肌梗死、中风和冠状动脉重建风险的瑞帕塔（Repatha）；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的阿拉内斯普（Aranesp）；用于治疗绝经后男性和女性骨质疏松症的伊文尼蒂（EVENITY）；用于治疗野生型 RAS 转移性结直肠癌患者的维克替胞（Vectibix）；用于治疗急性淋巴细胞白血病患者的布林西托（BLINCYTO）；用于治疗甲状腺眼病的泰珀扎（TEPEZZA）；以及用于治疗慢性难治性痛风的克里斯特克萨（KRYSTEXXA）。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们比安进更喜欢的股票</li>
<li>投资者如何从盘后交易中受益</li>
<li>瓦尔格林股价暴跌背后的原因：投资者下一步该怎么做</li>
<li>道指狗策略背后的原理和示例</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
<li>什么是标普 500 指数及其与其他指数的区别</li>
<li>通用磨坊财报季度四营收不及预期后股价下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 意想不到的选举震撼…（但你会看到它的到来）（来自 Banyan Hill Publishing）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk4"/></p>
<h2>现在是否值得投资 1000 美元购买安进股票？</h2>
<p>在考虑购买安进股票之前，您应该听听这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票清单…而安进并不在其中。</p>
<p>虽然安进目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

安进

<p>萨耶公司在第一季度将其在安进公司的持仓减少了 65.2%。其他机构投资者和对冲基金也对该公司的持仓进行了调整。分析师对该股票的评级大多是积极的。另外，高级副总裁南希·A·格里吉尔出售了该公司股票。安进公司的股票表现一直是积极的</p>

<p>Sawyer &amp; Company Inc decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 65.2% in the 1st quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 15,853 shares of the medical research company's stock after selling 29,752 shares during the period. Amgen makes up 1.8% of Sawyer &amp; Company Inc's portfolio, making the stock its 17th largest position. Sawyer &amp; Company Inc's holdings in Amgen were worth $4,507,000 at the end of the most recent quarter.</p>
<ul>
<li>Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines</li>
</ul>
<div class="lb-trans"><p>Sawyer &amp; Company Inc 在第一季度减持了 Amgen Inc.（纳斯达克股票代码：AMGN - 免费报告）的持股比例，根据最近向证券交易委员会提交的文件。该公司在此期间卖出了 29,752 股，持有这家医疗研究公司的股票 15,853 股。在 Sawyer &amp; Company Inc 的投资组合中，Amgen 占比 1.8%，是其第 17 大持仓。截至最近一个季度末，Sawyer &amp; Company Inc 对 Amgen 的持股价值为 4,507,000 美元。</p>
<ul>
<li>Moderna 股价飙升，因推出尖端个性化癌症疫苗</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Diversified Trust Co boosted its stake in Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company's stock worth $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group boosted its stake in Amgen by 11.9% in the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company's stock worth $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. boosted its stake in Amgen by 33.0% in the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company's stock worth $3,269,000 after purchasing an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. boosted its stake in Amgen by 2.4% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company's stock worth $1,363,000 after purchasing an additional 109 shares during the period. Finally, Traynor Capital Management Inc. boosted its stake in Amgen by 9.5% in the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company's stock worth $5,455,000 after purchasing an additional 1,650 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对该公司的持股进行了调整。Diversified Trust Co 在第四季度将其在 Amgen 的持股比例提高了 76.8%。Diversified Trust Co 现在拥有 37,695 股 Amgen 的股票，价值 10,857,000 美元，比之前增持了 16,376 股。Provence Wealth Management Group 在第四季度将其在 Amgen 的持股比例提高了 11.9%。Provence Wealth Management Group 现在拥有 1,445 股 Amgen 的股票，价值 416,000 美元，比之前增持了 154 股。Kinsale Capital Group Inc.在第四季度将其在 Amgen 的持股比例提高了 33.0%。Kinsale Capital Group Inc.现在拥有 11,348 股 Amgen 的股票，价值 3,269,000 美元，比之前增持了 2,814 股。Global Wealth Management Investment Advisory Inc.在第四季度将其在 Amgen 的持股比例提高了 2.4%。Global Wealth Management Investment Advisory Inc.现在拥有 4,733 股 Amgen 的股票，价值 1,363,000 美元，比之前增持了 109 股。最后，Traynor Capital Management Inc.在第四季度将其在 Amgen 的持股比例提高了 9.5%。Traynor Capital Management Inc.现在拥有 18,941 股 Amgen 的股票，价值 5,455,000 美元，比之前增持了 1,650 股。机构投资者和对冲基金拥有公司股份的 76.50%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities analysts recently weighed in on the stock. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, April 17th. Truist Financial restated a &#34;buy&#34; rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. StockNews.com upgraded shares of Amgen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Friday, May 3rd. Barclays upgraded shares of Amgen from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and increased their price objective for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, Argus increased their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Amgen has an average rating of &#34;Moderate Buy&#34; and an average price target of $307.35.</p>
<ul>
<li>Biotech Sector Nears Breakout: Will it Outperform in Q2?</li>
</ul>
<div class="lb-trans"><p>一些股票分析师最近对该股发表了意见。TD Cowen 将 Amgen 的目标股价从 370.00 美元降至 360.00 美元，并在 4 月 17 日星期三的研究报告中为该公司设定了 “买入” 评级。Truist Financial 在 4 月 12 日星期五的研究报告中重申了对 Amgen 的 “买入” 评级，并设定了 320.00 美元的价格目标。StockNews.com 在 5 月 3 日星期五的研究报告中，将 Amgen 的股票评级从 “持有” 调升至 “买入”。巴克莱在 5 月 3 日星期五的研究报告中，将 Amgen 的股票评级从 “轻仓” 调升至 “等权”，并将股票的价格目标从 230.00 美元提高至 300.00 美元。最后，阿格斯在周四的研究报告中，将 Amgen 的股票价格目标从 300.00 美元提高至 340.00 美元，并给予该股票 “买入” 评级。十位投资分析师对该股进行了持有评级，十二位分析师对该股进行了买入评级。根据 MarketBeat 的数据，Amgen 的平均评级为 “中性买入”，平均目标股价为 307.35 美元。</p>
<ul>
<li>生物科技行业接近突破：第二季度表现将优于市场吗？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on AMGN</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 AMGN 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>Amgen 内部交易</h2>
<ul>
<li>7 支将推动减肥药市场的股票</li>
</ul>
</div><p>In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company's stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Company insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>另外，高级副总裁 Nancy A. Grygiel 于 5 月 3 日星期五进行了一笔交易，出售了公司股票 2,117 股。这些股票的平均价格为 313.09 美元，交易总额为 662,811.53 美元。交易完成后，这位高级副总裁现在持有公司股票 9,883 股，价值 3,094,268.47 美元。该交易已在向证券交易委员会提交的法律文件中披露，可以通过此超链接获得。公司内部人士持有公司股份的比例为 0.69%。</p>
</div><h2>Amgen Stock Performance</h2>
<ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><h2>Amgen 股票表现</h2>
<ul>
<li>7 支将推动减肥药市场的股票</li>
</ul>
</div><p>NASDAQ AMGN opened at $312.45 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The firm has a market capitalization of $167.61 billion, a price-to-earnings ratio of 44.64, a P/E/G ratio of 2.83 and a beta of 0.60. The firm's 50 day simple moving average is $301.56 and its 200 day simple moving average is $292.10. Amgen Inc. has a 1 year low of $218.44 and a 1 year high of $329.72.</p>
<div class="lb-trans"><p>纳斯达克 AMGN 周五开盘价为 312.45 美元。该公司的流动比率为 1.42，速动比率为 0.98，负债权益比为 11.96。该公司的市值为 167.61 亿美元，市盈率为 44.64，市盈增长比率为 2.83，贝塔系数为 0.60。该公司的 50 天简单移动平均线为 301.56 美元，200 天简单移动平均线为 292.10 美元。Amgen Inc.的一年最低价为 218.44 美元，最高价为 329.72 美元。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts' consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter last year, the business posted $3.98 earnings per share. The company's quarterly revenue was up 22.0% on a year-over-year basis. As a group, research analysts expect that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Amgen（纳斯达克股票代码：AMGN - 获取免费报告）于 5 月 2 日星期四发布了其盈利结果。该医疗研究公司报告本季度每股盈利 3.96 美元，超过分析师对 3.76 美元的共识预期 0.20 美元。Amgen 的净利润率为 12.74%，净资产收益率为 156.21%。本季度，该公司的营收为 74.5 亿美元，略高于分析师对 74.5 亿美元的预期。与去年同期相比，公司的季度营收增长了 22.0%。研究分析师预计，Amgen Inc.本财年的每股盈利将达到 19.47 美元。</p>
</div><h2>Amgen Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Amgen 公司简介（免费报告）</h2>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>Amgen Inc（安进公司）在全球范围内发现、开发、生产和提供人类治疗药物。该公司的主要产品包括用于治疗斑块性银屑病、类风湿关节炎和银屑病性关节炎的安达治（Enbrel）；用于治疗成年患者斑块性银屑病、银屑病性关节炎和贝赫切特氏病口腔溃疡的奥特兹拉（Otezla）；用于治疗绝经后妇女骨质疏松症的普罗利亚（Prolia）；用于预防骨相关事件的 XGEVA；降低心肌梗死、中风和冠状动脉重建风险的瑞帕塔（Repatha）；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的阿拉内斯普（Aranesp）；用于治疗绝经后男性和女性骨质疏松症的伊文尼蒂（EVENITY）；用于治疗野生型 RAS 转移性结直肠癌患者的维克替胞（Vectibix）；用于治疗急性淋巴细胞白血病患者的布林西托（BLINCYTO）；用于治疗甲状腺眼病的泰珀扎（TEPEZZA）；以及用于治疗慢性难治性痛风的克里斯特克萨（KRYSTEXXA）。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Amgen</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>五只我们比安进更喜欢的股票</li>
<li>投资者如何从盘后交易中受益</li>
<li>瓦尔格林股价暴跌背后的原因：投资者下一步该怎么做</li>
<li>道指狗策略背后的原理和示例</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
<li>什么是标普 500 指数及其与其他指数的区别</li>
<li>通用磨坊财报季度四营收不及预期后股价下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ The Election SHOCK Nobody Expected… (But You’ll See it Coming) (From Banyan Hill Publishing)(Ad)</p>
<div class="lb-trans"><p>→ 意想不到的选举震撼…（但你会看到它的到来）（来自 Banyan Hill Publishing）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8598&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Amgen right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买安进股票？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买安进股票之前，您应该听听这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票清单…而安进并不在其中。</p>
</div><p>While Amgen currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sawyer & Company Inc 出售了 29,752 股安进公司（NASDAQ:AMGN）的股票